XClose

UK Dementia Research Institute at UCL

Menu

UK DRI at UCL Seminar: Ulf Neumann, Novartis Institute of BioMedical Research

18 September 2019, 3:00 pm–4:30 pm

UK Dementia Research Institute

Event Information

Open to

All

Organiser

Katharine Buckle

Location

Cruciform Foyer Meeting Room 1 (Boardroom)
Cruciform Building
Gower St, Fitzrovia
London
WC1E 6BT

BACE Inhibitor CNP520 for prevention of Alzheimer’s disease

Ulf Neumann, Novartis Institute of BioMedical Research, Basel, Switzerland

Ulf is a biochemist who has led the development of Novartis’ BACE inhibitor CNP520, which is currently tested in a prevention study involving cognitively normal homozygous ApoE4 carriers, or heterozygous carriers with 

evidence of brain amyloid, age 65 to 70. Ulf may share some thoughts on the recent clinical failure of BACE inhibitors from other companies, why Novartis’ compound may (hopefully) be different, and what else the company is doing to achieve the target of a cure for AD.


If you are interested in meeting with Ulf 1:1 you should contact Marc Busche at m.busche@ucl.ac.uk

About the Speaker

Ulf Neumann

at Novartis Institute of BioMedical Research